Silence Therapeutics plc (OTCMKTS:SLNCF – Get Free Report)’s share price fell 0.5% during mid-day trading on Monday . The stock traded as low as $2.20 and last traded at $2.20. 1,670 shares traded hands during mid-day trading, an increase of 34% from the average daily volume of 1,248 shares. The stock had previously closed at $2.21.
Silence Therapeutics Trading Down 0.5%
The stock has a 50-day moving average price of $1.79 and a 200 day moving average price of $1.77.
About Silence Therapeutics
Silence Therapeutics is a clinical-stage biotechnology company focused on the development of small interfering RNA (siRNA) therapies designed to silence disease-causing genes. The company’s proprietary AtuRNAi platform employs ligand-conjugated siRNA to enable targeted delivery and extended duration of action, with the aim of addressing chronic and severe diseases. Silence Therapeutics advances its own pipeline programs while also forming strategic partnerships to leverage its delivery technology in indications such as cardiovascular disease, metabolic disorders and rare genetic conditions.
The company’s lead program, SLN360, is designed to reduce lipoprotein(a), a known independent risk factor for cardiovascular events, and is currently in clinical development.
Read More
- Five stocks we like better than Silence Therapeutics
- Buy CrowdStrike Before the Stock Split? Here’s the Case
- Investors Are Buying Into Sweetgreen Again—Should They?
- Burlington Is Winning Over Shoppers But Investors Need Patience
- USA Today’s Digital Revival Is Gaining Steam, But With Plenty of Risk
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
